Literature DB >> 27144793

Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.

Ariss DerHovanessian1, Jamie L Todd2, Alice Zhang1, Ning Li3, Aradhna Mayalall1, C Ashley Finlen Copeland2, Michael Shino1, Elizabeth N Pavlisko4, W Dean Wallace5, Aric Gregson6, David J Ross1, Rajan Saggar1, Joseph P Lynch1, John Belperio1, Laurie D Snyder2, Scott M Palmer2, S Sam Weigt1.   

Abstract

RATIONALE: The clinical course of chronic lung allograft dysfunction (CLAD) is heterogeneous. Forced vital capacity (FVC) loss at onset, which may suggest a restrictive phenotype, was associated with worse survival for bilateral lung transplant recipients in one previously published single-center study.
OBJECTIVES: We sought to replicate the significance of FVC loss in an independent, retrospectively identified cohort of bilateral lung transplant recipients and to investigate extended application of this approach to single lung recipients.
METHODS: FVC loss and other potential predictors of survival after the onset of CLAD were assessed using Kaplan-Meier and Cox proportional hazards models.
MEASUREMENTS AND MAIN RESULTS: FVC loss at the onset of CLAD was associated with higher mortality in an independent cohort of bilateral lung transplant recipients (hazard ratio [HR], 2.75; 95% confidence interval [CI], 2.02-3.73; P < 0.0001) and in a multicenter cohort of single lung recipients (HR, 1.80; 95% CI, 1.09-2.98; P = 0.02). Including all subjects, the deleterious impact of FVC loss on survival persisted after adjustment for other relevant clinical variables (HR, 2.36; 95% CI, 1.77-3.15; P < 0.0001). In patients who develop CLAD without FVC loss, chest computed tomography features suggestive of pleural or parenchymal fibrosis also predicted worse survival in both bilateral (HR, 2.01; 95% CI, 1.16-5.20; P = 0.02) and single recipients (HR, 2.47; 95% CI, 1.24-10.57; P = 0.02).
CONCLUSIONS: We independently validated the prognostic significance of FVC loss for bilateral lung recipients and demonstrated that this approach to CLAD classification also confers prognostic information for single lung transplant recipients. Improved understanding of these discrete phenotypes is critical to the development of effective therapies.

Entities:  

Keywords:  bronchiolitis obliterans; graft rejection; lung transplantation; spirometry

Mesh:

Year:  2016        PMID: 27144793      PMCID: PMC5018895          DOI: 10.1513/AnnalsATS.201510-719OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  22 in total

1.  Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.

Authors:  C Ashley Finlen Copeland; Laurie D Snyder; David W Zaas; W Jackson Turbyfill; W Austin Davis; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

2.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation.

Authors:  Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill
Journal:  J Heart Lung Transplant       Date:  2005-06-04       Impact factor: 10.247

3.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

4.  Acute antibody-mediated rejection after lung transplantation.

Authors:  Chad A Witt; Joseph P Gaut; Roger D Yusen; Derek E Byers; Jennifer A Iuppa; K Bennett Bain; G Alexander Patterson; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem
Journal:  J Heart Lung Transplant       Date:  2013-08-13       Impact factor: 10.247

5.  Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation.

Authors:  James P Woodrow; Oksana A Shlobin; Scott D Barnett; Nelson Burton; Steven D Nathan
Journal:  J Heart Lung Transplant       Date:  2010-06-26       Impact factor: 10.247

6.  Reestablishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome.

Authors:  Dana L Willner; Philip Hugenholtz; Stephanie T Yerkovich; Maxine E Tan; Joshua N Daly; Nancy Lachner; Peter M Hopkins; Daniel C Chambers
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

7.  Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.

Authors:  Laurie D Snyder; Ziwei Wang; Dong-Feng Chen; Nancy L Reinsmoen; C Ashley Finlen-Copeland; W Austin Davis; David W Zaas; Scott M Palmer
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

8.  Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study.

Authors:  S S Weigt; C A Finlen Copeland; A Derhovanessian; M Y Shino; W A Davis; L D Snyder; A L Gregson; R Saggar; J P Lynch; D J Ross; A Ardehali; R M Elashoff; S M Palmer; J A Belperio
Journal:  Am J Transplant       Date:  2013-02-07       Impact factor: 8.086

9.  CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction.

Authors:  Michael Y Shino; S Samuel Weigt; Ning Li; Vyacheslav Palchevskiy; Ariss Derhovanessian; Rajan Saggar; David M Sayah; Aric L Gregson; Michael C Fishbein; Abbas Ardehali; David J Ross; Joseph P Lynch; Robert M Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

10.  Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.

Authors:  Allan R Glanville; Christina L Aboyoun; Adrian Havryk; Marshall Plit; Steven Rainer; Monique A Malouf
Journal:  Am J Respir Crit Care Med       Date:  2008-02-08       Impact factor: 21.405

View more
  14 in total

1.  Fibroproliferation in chronic lung allograft dysfunction: Association of mesenchymal cells in bronchoalveolar lavage with phenotypes and survival.

Authors:  Michael P Combs; Meng Xia; David S Wheeler; Elizabeth A Belloli; Natalie M Walker; Russell R Braeuer; Dennis M Lyu; Susan Murray; Vibha N Lama
Journal:  J Heart Lung Transplant       Date:  2020-04-19       Impact factor: 10.247

2.  Effect of Lung Transplantation on Health-Related Quality of Life in the Era of the Lung Allocation Score: A U.S. Prospective Cohort Study.

Authors:  J P Singer; P P Katz; A Soong; P Shrestha; D Huang; J Ho; M Mindo; J R Greenland; S R Hays; J Golden; J Kukreja; M E Kleinhenz; R J Shah; P D Blanc
Journal:  Am J Transplant       Date:  2017-01-03       Impact factor: 8.086

Review 3.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

4.  Gene Expression Profiling of Bronchoalveolar Lavage Cells During Aspergillus Colonization of the Lung Allograft.

Authors:  S Samuel Weigt; Xiaoyan Wang; Vyacheslav Palchevskiy; Naman Patel; Ariss Derhovanessian; Michael Y Shino; David M Sayah; Joseph P Lynch; Rajan Saggar; David J Ross; Bernie M Kubak; Abbas Ardehali; Scott Palmer; Shahid Husain; John A Belperio
Journal:  Transplantation       Date:  2018-06       Impact factor: 4.939

5.  Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction.

Authors:  Jamie L Todd; Megan L Neely; C A Finlen Copeland; Courtney W Frankel; John M Reynolds; Scott M Palmer
Journal:  J Heart Lung Transplant       Date:  2018-10-31       Impact factor: 10.247

Review 6.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

7.  HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection.

Authors:  Yi-Ping Jin; Nicole M Valenzuela; Xiaohai Zhang; Enrique Rozengurt; Elaine F Reed
Journal:  J Immunol       Date:  2018-02-23       Impact factor: 5.422

Review 8.  Lung Transplantation: CT Assessment of Chronic Lung Allograft Dysfunction (CLAD).

Authors:  Anne-Laure Brun; Marie-Laure Chabi; Clément Picard; François Mellot; Philippe A Grenier
Journal:  Diagnostics (Basel)       Date:  2021-04-30

9.  The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction.

Authors:  M Y Shino; S S Weigt; N Li; A Derhovanessian; D M Sayah; R Saggar; R H Huynh; A L Gregson; A Ardehali; D J Ross; J P Lynch; R M Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2017-08-02       Impact factor: 9.369

10.  Top Ten Tips Palliative Care Clinicians Should Know About Solid Organ Transplantation.

Authors:  Naoka Murakami; Nathan D Baggett; Margaret L Schwarze; Keren Ladin; Andrew M Courtwright; Hilary J Goldberg; Eric P Nolley; Nelia Jain; Michael Landzberg; Kirsten Wentlandt; Jennifer C Lai; Myrick C Shinall; Nneka N Ufere; Christopher A Jones; Joshua R Lakin
Journal:  J Palliat Med       Date:  2022-03-11       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.